• Repligen swung to a third-quarter net loss of $38.43 million from a year-earlier profit.
• Operating results turned to a $29.5 million loss, primarily due to a $41.24 million intangible asset impairment charge.
• Revenue rose 11% year over year to $209.3 million.
• The BioLife Solutions acquisition closed October 6, expanding the company's cell therapy consumables portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270700PRIMZONEFULLFEED9853880) on October 27, 2026, and is solely responsible for the information contained therein.